Clinicopathological Characteristics in Combined Hepatocellular-Cholangiocarcinoma: A Single Center Study in Korea

被引:22
|
作者
Park, Hana [1 ]
Choi, Ki Hong [2 ,3 ]
Choi, Sae-Byeol [4 ]
Choi, Jong Won [1 ]
Kim, Do Young [1 ,3 ,5 ]
Ahn, Sang Hoon [1 ,3 ,5 ,6 ]
Kim, Kyung Sik [2 ,3 ]
Choi, Jin Sub [2 ,3 ]
Han, Kwang-Hyub [1 ,3 ,5 ,6 ]
Chon, Chae Yoon [1 ,3 ,5 ]
Park, Jun Yong [1 ,3 ,5 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea
[3] Yonsei Univ, Coll Med, Liver Canc Special Clin, Seoul 120752, South Korea
[4] Korea Univ, Coll Med, Dept Surg, Seoul 136705, South Korea
[5] Liver Cirrhosis Clin Res Ctr, Seoul, South Korea
[6] Brain Korea 21 Project Med Sci, Seoul, South Korea
关键词
Combined hepatocellular and cholangiocarcinoma; hepatocellular carcinoma; cholangiocarcinoma; PROGNOSTIC-FACTORS; CARCINOMA; FEATURES; RESECTION; CT;
D O I
10.3349/ymj.2011.52.5.753
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M : F=35 : 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.
引用
下载
收藏
页码:753 / 760
页数:8
相关论文
共 50 条
  • [31] Hepatocellular-cholangiocarcinoma with sarcomatous change: Clinicopathological features and outcomes
    Qian, Ye-Rong
    Jiang, Na
    Liu, Peng
    Zhang, Xu-Feng
    Liu, Xue-Min
    Lv, Yi
    Xiang, Jun-Xi
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2021, 20 (06) : 574 - 578
  • [32] Hepatocellular-cholangiocarcinoma with sarcomatous change:Clinicopathological features and outcomes
    Ye-Rong Qian
    Na Jiang
    Peng Liu
    Xu-Feng Zhang
    Xue-Min Liu
    Yi Lv
    Jun-Xi Xiang
    Hepatobiliary & Pancreatic Diseases International, 2021, 20 (06) : 574 - 578
  • [33] Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study
    Sasaki, Motoko
    Sato, Yasunori
    Nakanuma, Yasuni
    VIRCHOWS ARCHIV, 2024, 484 (06) : 915 - 923
  • [34] Clinicopathological features of combined hepatocellular-cholangiocarcinoma with sarcomatous change Case report and literature review
    Gu, Qianru
    Yu, Xia
    Chen, Hanbin
    Chen, Guorong
    MEDICINE, 2018, 97 (03)
  • [35] Carcinoma of ectopic liver tissue shares characteristics with combined hepatocellular-cholangiocarcinoma
    Geng, Shi-Kai
    Zhou, Jian-Hong
    Liu, You-Jun
    Xu, Li-Ping
    Wang, Nong-Rong
    Sun, Jian
    Chen, Nan-Ping
    Yu, Xue-Feng
    Deng, Jun
    Yin, Sheng-Jiang
    Wang, Meng-Meng
    Su, Yue
    Lu, Qi
    Qu, Qiang-Guan
    Yi, Fan
    Mei, Jin-Hong
    Feng, Qiong
    Gong, Zhi-Qiang
    Yang, Hong-Wu
    Deng, Huan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (11): : 12142 - 12153
  • [36] COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA: AN INDICATION FOR LIVER TRANSPLANTATION?
    Schaefer, I. -M.
    Reinecke, J. A.
    Goralczyk, A.
    Schultze, F. C.
    Amanzada, A.
    Schweyer, S.
    Lorf, T.
    Obed, A.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 39 - 39
  • [37] Combined hepatocellular-cholangiocarcinoma - A histopathologic, immunohistochemical, and in situ hybridization study
    Tickoo, SK
    Zee, SY
    Obiekwe, S
    Xiao, H
    Koea, J
    Robiou, C
    Blumgart, LH
    Jarnagin, W
    Ladanyi, M
    Klimstra, DS
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (08) : 989 - 997
  • [38] Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience
    Trikalinos, Nikolaos A.
    Zhou, Amy
    Doyle, Maria B. Majella
    Fowler, Kathryn J.
    Morton, Ashley
    Vachharajani, Neeta
    Amin, Manik
    Keller, Jesse W.
    Chapman, William C.
    Brunt, Elizabeth M.
    Tan, Benjamin R.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (10): : 1193 - 1199
  • [39] EXPRESSION OF ABH AND LEWIS BLOOD-GROUP ANTIGENS IN COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA - POSSIBLE EVIDENCE FOR THE HEPATOCELLULAR ORIGIN OF COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    OKADA, Y
    JINNO, K
    MORIWAKI, S
    MORICHIKA, S
    TORIGOE, SI
    ARIMA, T
    NAGASHIMA, H
    KOPROWSKI, H
    CANCER, 1987, 60 (03) : 345 - 352
  • [40] Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center
    Zhan, Qian
    Shen, Bai-Yong
    Deng, Xia-Xing
    Zhu, Zhe-Cheng
    Chen, Hao
    Peng, Chen-Hong
    Li, Hong-Wei
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (04) : 361 - 369